Elixion Biotech validates its quantum-informed R&D process

Elixion Biotech has emerged from stealth with a breakthrough that it claims could reshape early-stage drug discovery.

In just eleven months, and without external funding, the Zurich, Switzerland-based therapeutics company has validated its quantum physics-informed R&D process, confirming its ability to accurately predict and identify novel drug targets. The milestone positions Elixion to advance its precision-oncology pipeline and opens the door to seed-stage investment.

Elixion’s first validation program targets breast cancer, one of the leading causes of cancer-related mortality worldwide. Within this area, HER2-negative and triple-negative breast cancers (TNBC) remain among the most challenging to treat and represent major unmet needs. The results confirm that Elixion’s quantum-informed approach can accurately recover known biomarkers such as HER2/ERBB2, ESR1, BRCA1, and BRCA2, and identify new, clinically relevant therapeutic targets and molecular pathways not detected through conventional methods.